• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Goodwin Biotech, MD Anderson collaborate on GMP manufacturing of fusion protein conjugate

Goodwin Biotech, MD Anderson collaborate on GMP manufacturing of fusion protein conjugate

June 4, 2012
CenterWatch Staff

Goodwin Biotechnology (GBI) of Plantation, Fla., and the University of Texas MD Anderson Cancer Center have collaborated on process development and GMP manufacturing of a fusion protein composed of a vascular endothelial growth factor (VEGF) and the recombinant toxin, Gelonin (rGel), conjugated to a DOTA chelator.

GBI has already completed process development and is readying for the GMP manufacture of the drug conjugate. The GMP manufactured drug conjugate will subsequently be radiolabeled with 64Cu and evaluated in an early stage, human clinical trial. The fusion protein targets the tumor neovasculature, or blood supply, and inhibits tumor growth, and the DOTA chelator facilitates the subsequent labeling with a radioisotope for diagnostic imaging and/or therapeutics.

"The conjugate we are developing will hopefully enhance our ability to detect and treat primary cancers sooner, but it may also more accurately identify and inhibit metastatic spread earlier in the course of the disease,” said Michael G. Rosenblum, Ph.D., head of immunopharmacology and targeted therapy laboratory, and director of research development in experimental therapeutics at MD Anderson. 

"Contributing to such a medical advance is exciting," added Muctarr Sesay, PhD, vice president of process development, GBI. "We have a long history of collaborating with Dr. Rosenblum and MD Anderson for GMP manufacturing of therapeutic antibody drug conjugates that have been used in human clinical trials. With the current project, we are also leveraging our extensive experience with preparing conjugates for subsequent radioisotope labeling to develop this important product for diagnostic and therapeutic applications."

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing